Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Fixed-Duration Epcoritamab + R-Mini-CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Ineligible for Full-Dose R-CHOP: Updated Results from Arm 8 of the Epcore NHL-2 Trial

Lori A. Leslie, Chan Y. Cheah, Franck Morschhauser, Justin M. Darrah, Joshua Brody, David Belada, Juraj Duras, Joost S.P. Vermaat, Gerardo Musuraca, Kojo Osei-Bonsu, Yi Hao, Kimberly G. Archer, Monica Wielgos-Bonvallet, Ali Rana, Yasmin H. Karimi

Blood (2024) 144 (Supplement 1): 3106.

https://doi.org/10.1182/blood-2024-199652

Published: 2024

Journal Articles

The Survival Improvement of Transplant-Eligible Primary CNS Lymphoma Patients within Last 15 Years

Prokop Vodicka, Katerina Benesova, Andrea Janikova, David Belada, Andrea Hruskova, Heidi Mocikova, Juraj Duras, Katerina Steinerova, Alice Sykorova, Michal Masar, Jitka Dlouha, Petra Blahovcova, Marek Trneny

Blood (2024) 144 (Supplement 1): 1697.

https://doi.org/10.1182/blood-2024-208416

Published: 2024

Journal Articles

PCNSL Patients Treated with the Matrix Regimen in the Real World Have Similar Outcome to Those in the IELSG 32 Trial

Prokop Vodicka, Katerina Benesova, Andrea Janikova, David Belada, Veronika Hanackova, Heidi Mocikova, Juraj Duras, Katerina Steinerova, Eva Konirova, Tomas Prochazka, Kamila Polgarova, Jitka Dlouha, Petra Blahovcova, Marek Trneny

Blood (2024) 144 (Supplement 1): 1711.

https://doi.org/10.1182/blood-2024-204795

Published: 2024

Journal Articles

Epcoritamab SC + R-Mini-CHOP Leads to High Complete Metabolic Response Rates in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Ineligible for Full-Dose R-CHOP: First Disclosure from Arm 8 of the Epcore NHL-2 Trial

Joost S.P Vermaat, Joshua Brody, Juraj Ďuraš, Yasmin H. Karimi, Chan Y. Cheah, Justin M. Darrah, Gerardo Musuraca, Franck Morschhauser, Daniela Hoehn, Ali Rana, Yaou Song, Pegah Jafarinasabian, David Belada

Blood (2023) 142 (Supplement 1): 4457.

https://doi.org/10.1182/blood-2023-180935

Published: 2023

Journal Articles

Do the Control Cohorts of Phase III Randomized Trials Reflect the Real-World Results of DLBCL Patients?

Prokop Vodicka, Andrea Janikova, David Belada, Heidi Mocikova, Vit Prochazka, Juraj Duras, Katerina Steinerova, Vit Campr, Katerina Benesova, Samuel Hricko, Alice Sykorova, Petra Blahovcova, Radek Jaksa, Magdalena Klanova, Marek Trněný

Blood (2023) 142 (Supplement 1): 4485.

https://doi.org/10.1182/blood-2023-185620

Published: 2023

Journal Articles

The Outcome of Diffuse Large B-Cell Lymphoma Patients with Testicular Involvement - Real World Data

Heidi Mocikova, Andrea Janikova, Alice Sykorova, Vit Prochazka, Jan Pirnos, Juraj Duras, Katerina Kopeckova, Katerina Steinerova, Robert Pytlik, Petra Blahovcova, David Salek, Tomas Kozak, Veronika Bachanova, David Belada

Blood (2023) 142 (Supplement 1): 4482.

https://doi.org/10.1182/blood-2023-180155

Published: 2023

Journal Articles

Survival of Patients with Primary Mediastinal B-Cell Lymphoma Treated By Immunochemotherapy with or without Radiotherapy

Kamila Polgarova, Andrea Janíková, David Belada, Vit Prochazka, Juraj Ďuraš, Heidi Móciková, Kateřina Steinerová, Vít Campr, Petra Blahovcová, David Zogala, Václav Ptáčník, Marek Trneny

Blood (2022) 140 (Supplement 1): 3831–3832.

https://doi.org/10.1182/blood-2022-163113

Published: 2022

Journal Articles

How Relevant Are the Control Cohorts of Clinical Trials in Patients with Newly Diagnosed DLBCL in a Daily Practice?

Prokop Vodicka, Katerina Benesova, Andrea Janikova, David Belada, Heidi Mocikova, Jan Pirnos, Vit Prochazka, Juraj Duras, Katerina Kopeckova, Katerina Steinerova, Petra Blahovcova, Vit Campr, Pavel Klener, Jr., Alice Sykorova, Marek Trneny

Blood (2022) 140 (Supplement 1): 3775–3776.

https://doi.org/10.1182/blood-2022-159408

Published: 2022

Journal Articles

Is It Better to Start Treatment with ABVD and Continue with PET2-Adapted Approach or Should We Use 2 Cycles of Beacopp Escalated and 2 Cycles of ABVD and Irradiation in Early Unfavorable Hodgkin Lymphoma?

Heidi Mocikova, Jana Markova, Lubica Gaherova, Maria Maco, Alice Sykorova, David Belada, Marie Lukasova, Vit K Prochazka, Katarina Hradska, Juraj Ďuraš, Ondrej Havranek, Tomas Kozak

Blood (2021) 138 (Supplement 1): 4539.

https://doi.org/10.1182/blood-2021-148363

Published: 2021

Journal Articles

Bayesian Network Modelling As a New Tool in Predicting of the Early Progression of Disease in Follicular Lymphoma Patients

Vít K Procházka, Štěpánka Matuštíková, Tomáš Fürst, Dr., David Belada, MD PhD, Andrea Janíková, MD PhD Assoc Prof, Kateřina Benešová, MD PhD, Heidi Mociková, MD, Juraj Ďuraš, MD, Jan Pirnos, MD, Kateřina Kopečková, MD PhD, Vít Campr, MD PhD, Jozef Michalka, MD, Robert Pytlík, MD, Tomáš Papajík, MD prof, Marek Trněný, MD prof

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-139830

Published: 2020

Journal Articles

Early Follicular Lymphoma Progression in Patients Treated with Frontline Immunochemotherapy with/without Rituximab Maintenance: Clinically Meaningful Even in Chemosensitive Individuals

Vit K Prochazka, MD prof, David Belada, MD PhD, Andrea Janikova, MD PhD Assoc Prof, Katerina Benesova, MD PhD, Heidi Mocikova, MD PhD, Juraj Duras, MD, Robert Pytlik, MD PhD, Jan Pirnos, MD, Alice Sýkorová, MD PhD, Vit Campr, MD PhD, Jozef Michalka, MD, Kateřina Kopečková, MD PhD, Jitka Dlouha, Tomas Papajik, MD prof, Marek Trneny, MD prof

Blood (2019) 134 (Supplement_1): 3983.

https://doi.org/10.1182/blood-2019-129756

Published: 2019

Journal Articles

Towards Higher Safety of Haemato-Oncological Patients Undergoing Treatment

Tereza Popkova, MD, Katarina Hradska, MD, Jana Mihalyova, MD, Michaela Skorupova, Tomas Jelinek, MD, Juraj Duras, MD, Zdenek Koristek, MD PhD, Milan Navratil, MD, Katerina Benkova, MD, Hana Plonkova, MD, Jana Zuchnicka, MD, Jaromir Gumulec, MD, Roman Hajek, Prof, MD PhD

Blood (2019) 134 (Supplement_1): 4757.

https://doi.org/10.1182/blood-2019-127011

Published: 2019

Journal Articles

The Fate of Patients with Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Pavel Otahal, MD PhD, Andrea Janikova, MD PhD Assoc Prof, David Belada, MD PhD, Vit Prochazka, MD, Heidi Mocikova, MD PhD, Jan Pirnos, Juraj Ďuraš, Kateřina Kopečková, Vit Campr, MD PhD, Robert Pytlik, Petra Blahovcova, Mgr, Marek Trneny, MD CSc

Blood (2018) 132 (Supplement 1): 5413.

https://doi.org/10.1182/blood-2018-99-117110

Published: 2018

Journal Articles

Population-Based Analysis of Elderly Patients (>70 YEARS) with Peripheral T-CELL Lymphoma: A Results from Czech Lymphoma Study Group (CLSG) Registry

Andrea Janikova, MD PhD, Assoc Prof, Robert Pytlik, MD, Pavel Klener, MD PhD, Zbynek Bortlicek, PhD, Vit Campr, MD PhD, Natasa Kopalova, Mgr, Katerina Benesova, MD PhD, Michaela Hamouzova, David Belada, MDPhD, Vit Prochazka, MD PhD ass. prof., Jan Pirnos, MD, Juraj Duras, MD, Heidi Mocikova, MD, PhD, Jiri Mayer, MD, Marek Trneny

Blood (2016) 128 (22): 3000.

https://doi.org/10.1182/blood.V128.22.3000.3000

Published: 2016

Journal Articles

Low Hodgkin/Reed-Sternberg Cell Density Assessed with Automated Image Analysis Is a Poor Prognostic Factor in Classic Hodgkin Lymphoma Patients

Vit Prochazka, MD PhD ass. prof., Tereza Dyskova, Dr., Zuzana Prouzova, MD, Tomas Papajik, MD PhD prof., Jiri Minarik, MD PhD, Juraj Duras, MD, Jozef Michalka, MD, Alice Sykorova, MD PhD, Peter Mikula, MD, Ludek Raida, MD PhD, Eva Kriegova, Dr., PhD

Blood (2015) 126 (23): 4999.

https://doi.org/10.1182/blood.V126.23.4999.4999

Published: 2015

Journal Articles

The Outcome of Mantle Cell Lymphoma patients after Treatment Failure and Prognostic value of Secondary Mantle Cell International Prognostic Index (sec MIPI)

Marek Trneny, MD, Pavel Klener, MD, David Belada, MD, Heidi Mocikova, MD, PhD, Vit Prochazka, MD, Samuel Vokurka, MD PhD, Jan Pirnos, MD, Katerina Kubackova, MD, Juraj Duras, MD, Jana Salkova, MD, David Salek, MD, Robert Pytlik, MD, PhD, Lucie Barsova, MD, Petr Kessler, MD, Ludmila Boudova, MD, Vit Campr, MD, PhD, Radek Jaksa, MD, Jitka Dlouha, Katerina Benesova, MD

Blood (2014) 124 (21): 4425.

https://doi.org/10.1182/blood.V124.21.4425.4425

Published: 2014

NARROW

Fixed-Duration Epcoritamab + R-Mini-CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Ineligible for Full-Dose R-CHOP: Updated Results from Arm 8 of the Epcore NHL-2 Trial

The Survival Improvement of Transplant-Eligible Primary CNS Lymphoma Patients within Last 15 Years

PCNSL Patients Treated with the Matrix Regimen in the Real World Have Similar Outcome to Those in the IELSG 32 Trial

Epcoritamab SC + R-Mini-CHOP Leads to High Complete Metabolic Response Rates in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Ineligible for Full-Dose R-CHOP: First Disclosure from Arm 8 of the Epcore NHL-2 Trial

Do the Control Cohorts of Phase III Randomized Trials Reflect the Real-World Results of DLBCL Patients?

The Outcome of Diffuse Large B-Cell Lymphoma Patients with Testicular Involvement - Real World Data

Survival of Patients with Primary Mediastinal B-Cell Lymphoma Treated By Immunochemotherapy with or without Radiotherapy

How Relevant Are the Control Cohorts of Clinical Trials in Patients with Newly Diagnosed DLBCL in a Daily Practice?

Is It Better to Start Treatment with ABVD and Continue with PET2-Adapted Approach or Should We Use 2 Cycles of Beacopp Escalated and 2 Cycles of ABVD and Irradiation in Early Unfavorable Hodgkin Lymphoma?

Bayesian Network Modelling As a New Tool in Predicting of the Early Progression of Disease in Follicular Lymphoma Patients

Early Follicular Lymphoma Progression in Patients Treated with Frontline Immunochemotherapy with/without Rituximab Maintenance: Clinically Meaningful Even in Chemosensitive Individuals

Towards Higher Safety of Haemato-Oncological Patients Undergoing Treatment

The Fate of Patients with Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Population-Based Analysis of Elderly Patients (>70 YEARS) with Peripheral T-CELL Lymphoma: A Results from Czech Lymphoma Study Group (CLSG) Registry

Low Hodgkin/Reed-Sternberg Cell Density Assessed with Automated Image Analysis Is a Poor Prognostic Factor in Classic Hodgkin Lymphoma Patients

The Outcome of Mantle Cell Lymphoma patients after Treatment Failure and Prognostic value of Secondary Mantle Cell International Prognostic Index (sec MIPI)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only